Centessa Pharmaceuticals Limited (CNTA): Price and Financial Metrics Recent IPO

Centessa Pharmaceuticals Limited (CNTA): $20.64

-0.43 (-2.04%)

POWR Rating

Component Grades













CNTA Stock Price Chart Interactive Chart >

Price chart for CNTA

CNTA Price/Volume Stats

Current price $20.64 52-week high $26.90
Prev. close $21.07 52-week low $19.61
Day low $20.26 Volume 90,500
Day high $21.15 Avg. volume 239,507
50-day MA $0.00 Dividend yield N/A
200-day MA $0.00 Market Cap 1.86B

Centessa Pharmaceuticals Limited (CNTA) Company Bio

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.

CNTA Latest News Stream

Event/Time News Detail
Loading, please wait...

CNTA Latest Social Stream

Loading social stream, please wait...

View Full CNTA Social Stream

Latest CNTA News From Around the Web

Below are the latest news stories about Centessa Pharmaceuticals plc that investors may wish to consider to help them evaluate CNTA as an investment opportunity.

Centessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

CAMBRIDGE, Mass. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021, beginning at 5:30 p.m. Eastern Time. About Centessa PharmaceuticalsCentessa Pharmaceuticals plc aims to bring impactful new medicines to patients by combining the strengths of an asse

Yahoo | June 7, 2021

Citi Appointed as Depositary Bank for Centessa Pharmaceuticals plc’s ADR Programme

Citi, acting through Citibank N.A., has been appointed by Centessa Pharmaceuticals plc ("Centessa"), a next-generation biopharmaceutical company, to act as depositary bank for its American Depositary Receipt ("ADR") programme.

Yahoo | June 7, 2021

Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

CAMBRIDGE, Mass. and LONDON, June 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced today that, in connection with its previously announced initial public offering of 16,500,000 American Depositary Shares (“ADSs”), the underwriters have fully exercised their option to purchase an additional 2,475,000 ADSs at th

Yahoo | June 4, 2021

Centessa Announces Pricing of Initial Public Offering

Centessa Announces Pricing of Initial Public Offering

Yahoo | May 28, 2021

Read More 'CNTA' Stories Here

CNTA Price Returns

1-mo -6.69%
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6618 seconds.